<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01067846</url>
  </required_header>
  <id_info>
    <org_study_id>111989</org_study_id>
    <secondary_id>R21DA025243</secondary_id>
    <nct_id>NCT01067846</nct_id>
  </id_info>
  <brief_title>Cognitive Enhancement and Relapse Prevention in Cocaine Addiction</brief_title>
  <official_title>The Clinical and Neural Response of Cocaine Addicts to Combination Treatment With a Cognitive Enhancer and Extinction-Based Psychotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For this project, the investigators are interested in exploring a new way to extend and
      maintain drug abstinence in people who are addicted to crack cocaine. This study will combine
      a medication called D-Cycloserine (DCS) and weekly cognitive behavioral therapy (CBT) to
      assess whether the combination will enhance people's ability to stay clean (drug free) for
      longer periods of time.

      One of the greatest risks for drug relapse is drug craving. Oftentimes drug craving occurs
      when a person is confronted with stressors and reminders of past drug use behavior. DCS has
      been shown to enhance the learning of new information. By administering DCS prior to learning
      new techniques such as how to cope with drug craving and drug-use reminders, it is possible
      that patients can be more successful at living a drug free life for a longer period of time.

      In addition to exploring this model behaviorally, the investigators will explore changes that
      may occur in the brain before and after the therapy/medication intervention. A technique
      called MRI (Magnetic Resonance Imaging) will be used to identify areas of the brain that are
      being activated during an attention task. Areas of neural activation will be assessed at
      study entry, end of therapy (4-week endpoint) and one month following completion of the
      treatment program.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Hypothesis:

      Enhancing glutamatergic neurotransmission with DCS facilitates CBT-related relapse prevention
      by potentiating the behavioral and neural representation of the diminished drug motivation
      associated with cocaine cues.

      Specific Aims:

        1. Determine if the short-term oral administration of DCS relative to placebo prior to CBT
           sessions facilitates cocaine abstinence and functional recovery, and reduces cocaine
           craving in treatment-seeking cocaine addicts.

        2. Determine if DCS administration relative to placebo facilitates CBT-related decreases in
           the behavioral and neural response to conditioned cocaine cues.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Abstinence During Treatment and at Follow up Visits</measure>
    <time_frame>Participants provided urine samples for drug testing during treatment which occurred 3 times per week for 4 weeks, at the end of treatment, and at a 1 and 2 month follow up visit</time_frame>
    <description>Percentage of the overall number of drug abstinences of participants measured by urine drug testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Retention - Number of Visits During Treatment</measure>
    <time_frame>Treatment sessions included 3 visits per week for 4 weeks</time_frame>
    <description>Number of treatment visits attended prior to discontinuation of treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Cocaine Addiction</condition>
  <arm_group>
    <arm_group_label>DCS and Cognitive Behavioral Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 250 mg of Seromycin or D-cycloserine (DCS) prior to computerized cognitive behavioral therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Cognitive Behavioral Therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive a 250 mg identical looking placebo pill prior to computerized cognitive behavioral therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seromycin (D-cycloserine, DCS)</intervention_name>
    <description>250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.</description>
    <arm_group_label>DCS and Cognitive Behavioral Therapy</arm_group_label>
    <other_name>D-cycloserine, DCS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo identical looking to the 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.</description>
    <arm_group_label>Placebo and Cognitive Behavioral Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Computerized Cognitive Behavioral Therapy</intervention_name>
    <description>All participants received Computerized Cognitive Behavioral Therapy sessions 3 times per week for 4 weeks as a drug relapse intervention.</description>
    <arm_group_label>DCS and Cognitive Behavioral Therapy</arm_group_label>
    <arm_group_label>Placebo and Cognitive Behavioral Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible subjects must be cocaine-dependent persons between 18 and 65 years

        Exclusion Criteria:

          -  Any current Axis-I psychiatric diagnosis other than cocaine or alcohol dependence or
             nicotine use

          -  Any current or prior neurological disease, history of a major medical illness, or
             current use of psychotropic medications

          -  Positive history of loss of consciousness of greater than 10 min

          -  Significant current or prior cardiovascular disease (hypertension, arrhythmias) that
             is not medically stable

          -  History of hospitalization within the previous six months for a medical illness

          -  Deafness, blindness or other significant sensory impairment.

          -  Contraindications for D-cycloserine and magnetic resonance imaging.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinton Kilts, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Psychiatric Research Institute (PRI) (Center for Addiction Research (CAR) and Brain Imaging Research Center (BIRC)) University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2010</study_first_submitted>
  <study_first_submitted_qc>February 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2010</study_first_posted>
  <results_first_submitted>June 11, 2013</results_first_submitted>
  <results_first_submitted_qc>October 31, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 26, 2013</results_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cocaine dependence</keyword>
  <keyword>relapse prevention</keyword>
  <keyword>computerized cognitive behavioral therapy (CBT)</keyword>
  <keyword>D-cycloserine (DCS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behavior, Addictive</mesh_term>
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment included outpatient and inpatient alcohol and drug abuse clinics, self-referrals, flyers in public places, and advertisements in newspapers. Recruitment started June 2010 and ended September 2011.</recruitment_details>
      <pre_assignment_details>Enrolled participants could have been excluded due to other drug dependencies, loss of consciousness &gt; 10 min, neurologic disorder, severe hepatic insufficiency, significant cardiovascular disease, current psychiatric disorder, current medical illness, sensory impairment, positive pregnancy test.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DCS and Cognitive Behavioral Therapy</title>
          <description>Subjects will receive 250 mg of Seromycin or D-cycloserine (DCS) prior to computerized cognitive behavioral therapy.
Seromycin (D-cycloserine, DCS) : 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.</description>
        </group>
        <group group_id="P2">
          <title>Placebo and Cognitive Behavioral Therapy</title>
          <description>Subjects will receive a 250 mg identical looking placebo pill prior to computerized cognitive behavioral therapy.
Placebo : Placebo identical looking to the 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29">Due to exclusion prior to group assignment, Study Enrollment will not equal Total # of Participants.</participants>
                <participants group_id="P2" count="30">Due to exclusion prior to group assignment, Study Enrollment will not equal Total # of Participants.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 3 Tx Sessions</title>
              <participants_list>
                <participants group_id="P1" count="15">Our final analysis includes these participants.</participants>
                <participants group_id="P2" count="15">Our final analysis includes these participants.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10">Participants that completed all 4 weeks of treatment.</participants>
                <participants group_id="P2" count="11">Participants that completed all 4 weeks of treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>participation in other tx study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>These numbers include participants that were eligible after the initial intake assessment and were assigned to a group.</population>
      <group_list>
        <group group_id="B1">
          <title>DCS and Cognitive Behavioral Therapy</title>
          <description>Subjects will receive 250 mg of Seromycin or D-cycloserine (DCS) prior to computerized cognitive behavioral therapy.
Seromycin (D-cycloserine, DCS) : 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.</description>
        </group>
        <group group_id="B2">
          <title>Placebo and Cognitive Behavioral Therapy</title>
          <description>Subjects will receive a 250 mg identical looking placebo pill prior to computerized cognitive behavioral therapy.
Placebo : Placebo identical looking to the 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="6.67"/>
                    <measurement group_id="B2" value="45" spread="9.13"/>
                    <measurement group_id="B3" value="44" spread="7.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drug Abstinence During Treatment and at Follow up Visits</title>
        <description>Percentage of the overall number of drug abstinences of participants measured by urine drug testing</description>
        <time_frame>Participants provided urine samples for drug testing during treatment which occurred 3 times per week for 4 weeks, at the end of treatment, and at a 1 and 2 month follow up visit</time_frame>
        <population>Total possible urine samples = 225 per arm. Not all participants stayed in treatment, therefore the total units analyzed will not match the total possible.</population>
        <group_list>
          <group group_id="O1">
            <title>DCS and Cognitive Behavioral Therapy</title>
            <description>Subjects will receive 250 mg of Seromycin or D-cycloserine (DCS) prior to computerized cognitive behavioral therapy.
Seromycin (D-cycloserine, DCS) : 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Cognitive Behavioral Therapy</title>
            <description>Subjects will receive a 250 mg identical looking placebo pill prior to computerized cognitive behavioral therapy.
Placebo : Placebo identical looking to the 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Abstinence During Treatment and at Follow up Visits</title>
          <description>Percentage of the overall number of drug abstinences of participants measured by urine drug testing</description>
          <population>Total possible urine samples = 225 per arm. Not all participants stayed in treatment, therefore the total units analyzed will not match the total possible.</population>
          <units>percentage of drug abstinences</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Urine Samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment Retention – Number of Visits During Treatment</title>
        <description>Number of treatment visits attended prior to discontinuation of treatment</description>
        <time_frame>Treatment sessions included 3 visits per week for 4 weeks</time_frame>
        <population>Total possible sessions attended = 180 per arm. Some participants did not complete all sessions, therefore the units analyzed will not match the total possible.</population>
        <group_list>
          <group group_id="O1">
            <title>DCS and Cognitive Behavioral Therapy</title>
            <description>Subjects will receive 250 mg of Seromycin or D-cycloserine (DCS) prior to computerized cognitive behavioral therapy.
Seromycin (D-cycloserine, DCS) : 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Cognitive Behavioral Therapy</title>
            <description>Subjects will receive a 250 mg identical looking placebo pill prior to computerized cognitive behavioral therapy.
Placebo : Placebo identical looking to the 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Retention – Number of Visits During Treatment</title>
          <description>Number of treatment visits attended prior to discontinuation of treatment</description>
          <population>Total possible sessions attended = 180 per arm. Some participants did not complete all sessions, therefore the units analyzed will not match the total possible.</population>
          <units>visits</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Sessions Attended</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="3"/>
                    <measurement group_id="O2" value="10" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 7 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DCS and Cognitive Behavioral Therapy</title>
          <description>Subjects will receive 250 mg of Seromycin or D-cycloserine (DCS) prior to computerized cognitive behavioral therapy.
Seromycin (D-cycloserine, DCS) : 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.</description>
        </group>
        <group group_id="E2">
          <title>Placebo and Cognitive Behavioral Therapy</title>
          <description>Subjects will receive a 250 mg identical looking placebo pill prior to computerized cognitive behavioral therapy.
Placebo : Placebo identical looking to the 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <description>Participant reported a nauseas feeling. Physician determined it was not study related.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <description>Participant reported mild headaches. Physician determined it was not study related.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <description>Participant reported infrequent coughing. Physician determined it was not study related.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>sensation on skin</sub_title>
                <description>Participant reported a crawling sensation on skin. Physician determined it was not study related.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>rash on skin</sub_title>
                <description>Participant reported a rash on skin. Physician determined it was not study related.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clint Kilts, PhD</name_or_title>
      <organization>Brain Imaging Research Center</organization>
      <phone>526-8163</phone>
      <email>CDKilts@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

